BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, May 2, 2026
Home » Authors » Nuala Moran

Articles by Nuala Moran

GeneMedix Considers Merger, Plans U.S. Listing On Nasdaq

Feb. 18, 2004
By Nuala Moran

Ark Seeks Listing On London Stock Exchange Via £50 IPO

Feb. 11, 2004
By Nuala Moran
LONDON - Ark Therapeutics Group plc is feeling out investor appetite for what would be the first listing of a biotechnology company on the main market of the London Stock Exchange in three years. (BioWorld International)
Read More

CAT Reports CAT-192 Results With Genzyme, Ends Elan Deal

Feb. 11, 2004
By Nuala Moran

Ark Seeks Listing On London Stock Exchange Via £50 IPO

Feb. 11, 2004
By Nuala Moran
LONDON - Ark Therapeutics Group plc is feeling out investor appetite for what would be the first listing of a biotechnology company on the main market of the London Stock Exchange in three years. (BioWorld International)
Read More

CAT Reports CAT-192 Results With Genzyme, Ends Elan Deal

Feb. 11, 2004
By Nuala Moran

Acambis Moving R&D Core To U.S.,Cutting Work Force By 40

Feb. 4, 2004
By Nuala Moran

Cyclacel's Fourth Round Gets $39M For Cell Cycle Inhibitors

Feb. 4, 2004
By Nuala Moran
LONDON - Cyclacel Ltd. raised £21.3 million (US$39 million) in an oversubscribed fourth round of private funding, bringing its total private equity raised to date to $123 million. (BioWorld International)
Read More

Cyclacel's Fourth Round Gets $39M For Cell Cycle Inhibitors

Feb. 4, 2004
By Nuala Moran
LONDON - Cyclacel Ltd. raised £21.3 million (US$39 million) in an oversubscribed fourth round of private funding, bringing its total private equity raised to date to $123 million. (BioWorld International)
Read More

Acambis Moving R&D Core To U.S.,Cutting Work Force By 40

Feb. 4, 2004
By Nuala Moran

As GW's Sativex Is Reviewed, Extension-Study Data Grow

Jan. 28, 2004
By Nuala Moran
Previous 1 2 … 460 461 462 463 464 465 466 467 468 … 537 538 Next

Popular Stories

  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for April 28, 2026
  • Chinabio 2026 partnering

    Chinese biotechs gain leverage as partners in dealmaking

    BioWorld
    China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
  • AI generated image for researcher developing antisense oligonucleotides

    Bio Korea 2026 kicks off with spotlight on oligonucleotides

    BioWorld
    Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
  • Neurons

    AA meeting of minds as PTC, Novartis push votoplam in HD

    BioWorld
    What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
  • University of Western Australia patents 5-HT2A/B modulators

    BioWorld Science
    University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing